While none of the biomarkers analyzed, apart from CEA and the CEA density—LMR, NLR, PLR, AGR—are specific to CLM, their value stems from their ability to reflect the systemic inflammatory response and tumor burden, both of which have a well-established role in cancer progression and treatment outcomes. The gene discussed is CEACAM5; the disease is cancer.